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Background: Although genetically engineered cells have been used to generate monoclonal antibodies (mAbs)
against numerous proteins, no study has used them to generate mAbs against glycosylphosphatidylinositol
(GPI)-anchored proteins. The GPI-linked protein Rae-1, an NKG2D ligand member, is responsible for interacting with
immune surveillance cells. However, very few high-quality mAbs against Rae-1 are available for use in multiple
analyses, including Western blotting, immunohistochemistry, and flow cytometry. The lack of high-quality mAbs
limits the in-depth analysis of Rae-1 fate, such as shedding and internalization, in murine models. Moreover,
currently available screening approaches for identifying high-quality mAbs are excessively time-consuming and
costly.
Results: We used Rae-1–overexpressing CT26 tumor cells to generate 60 hybridomas that secreted mAbs against
Rae-1. We also developed a streamlined screening strategy for selecting the best anti–Rae-1 mAb for use in flow
cytometry assay, enzyme-linked immunosorbent assay, Western blotting, and immunostaining.
Conclusions: Our cell line–based immunization approach can yield mAbs against GPI-anchored proteins, and our
streamlined screening strategy can be used to select the ideal hybridoma for producing such mAbs.
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Since 1975, when Kohler and Milstein first reported pro-
ducing monoclonal antibodies (mAbs) by generating and
isolating hybridoma cells [1], mAbs have been broadly
used in research and therapy. At the same time, mAb
production methods have been improving.
Rae-1α, -1β, -1γ, -1δ, and -1ε are mouse NKG2D li-
gands that have been reported to have very low expres-
sion levels in the normal tissues of adult mice [2].
However, the expression of these ligands can be upregu-
lated in infectious tissues or tumor cell lines [3]. All
Rae-1 family members have GPI anchors that lack cyto-
plasmic domains. To produce an mAb targeting the
mouse NKG2D ligand Rae-1, one must overcome the in-
solubility problem and the post-translational modifica-
tions of the Rae-1 protein.* Correspondence: Sli4@mdanderson.org
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stated.In traditional mAb production, the first step is to pro-
duce the antigen of interest. For decades, live cells
whose surfaces endogenously display certain proteins
have been used as antigens to induce immune responses
in animals. In the 1980s, as eukaryotic vectors were
being developed, cells stably transfected with non-
endogenous proteins were used as antigens to produce
antibodies [4]. Some groups have reported that live
mammalian cells that express certain proteins on their
surfaces could be used to immunize animals to generate
mAbs [4,5]. In the present study, our objective was to
use a mouse cell line stably transfected with pBMN
Rae −1 GFP to show that cell-based immunization
can yield hybridomas to produce mAbs against the
glycosylphosphatidylinositol (GPI)-linked protein Rae-1.
In the present study, we applied a novel strategy of anti-
gen preparation and animal immunization to develop an
anti–Rae-1 mAb. We stably transfected full-length Rae-1δ
into murine CT26 cells using a retrovirus system, the vec-
tor transfected cells as control, and then immunizedThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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vector transfected cells. Thus, we describe how to use sta-
bly transfected cells as the GPI antigen to immunize ani-
mals to generate mAbs that could be used for enzyme-
linked immunosorbent assay (ELISA), Western blotting,
flow cytometry, immunofluorescence staining, immuno-
histochemistry, and potentially therapeutic purposes.
Materials and methods
Cell culture and establishment of a cell line stably
transfected with Rae-1
The cancer cell lines CT26, TC1, B16F10, LLC, K7M3,
and YAC-1 were obtained from American Type Culture
Collection (Rockville, MD, USA). CT26, TC1, K7M3,
B16F10, and LLC cells were grown in Dulbecco's modified
Eagle’s medium (Mediatech, Inc., Manassas, VA, USA)
supplemented with glutamine, heat-inactivated 10% fetal
calf serum, and 10 U/ml penicillin and streptomycin.
YAC-1 cells were grown in RPMI-1640 medium
(Mediatech, Inc.) supplemented with heat-inactivated
10% fetal calf serum and 10 U/ml penicillin and
streptomycin.
The murine gene Rae-1δ (Open Biosystems) was sub-
cloned into a pBMN–green fluorescent protein (GFP)
plasmid. Retroviruses were produced by transfecting
mRae-1δ/pBMN-GFP constructs into Phoenix-ECO
packaging cells. CT26 cells were infected with the
retrovirus-containing supernatant derived from the
transduced HEK293 cells. Cell colonies were expanded
from a single cell expressing GFP. Both Rae-1δ/GFP and
GFP-positive CT26 cells were confirmed using flow
cytometry.
Mouse immunization
Stable transfected cells were washed twice in phosphate-
buffered saline (PBS), counted, suspended in 100 μl of
sterile PBS, and then transferred to a 0.5-ml tuberculin
syringe. Six- to seven-week-old BALB/C mice were
injected with 35 × 106 cells in a 50-μl volume in each
foot. The mice received injections every 3 days for
18 days (6 injections total). On day 18, the mice were
humanely killed, and B cells were isolated from lymph
nodes for fusion.
Myeloma cells expansion
One week before fusion was to be performed, we began
growing SP2/0-Ag14 myeloma cells in a 10-cm petri
dish containing RPMI medium supplemented with 10%
FBS to ensure that 1 × 108 cells would be available for
fusion.
Mouse lymph nodes harvest
For the mouse lymph node harvest, we first prepared
RPMI medium containing 10% FBS, 1× PN/SM and1× hypoxanthine, aminopterin, and thymidine (HAT)
medium, and we prewarmed 50% polyethylene glycol
(PEG; Sigma) in a 37°C incubator. We then euthanized
the mice and aseptically harvested the lymph nodes. We
transferred the lymph nodes into a sterile 10-cm petri
dish containing 10 ml of serum-free RPMI medium. We
used forceps to manipulate the lymph nodes to release
cells and transferred the lymphocyte suspension to a
sterile 50-ml conical centrifuge tube that we then filled
with serum-free RPMI medium. We washed the cells 2
times with serum-free RPMI medium. To harvest the
Sp2/0-Ag14 myeloma cells, we transferred the cells into
50-ml conical centrifuge tubes and centrifuged them at
1150 rpm for 3 min at room temperature. After aspirat-
ing and discarding the supernatant, we resuspended the
SP2/0-Ag14 cells in serum-free RPMI medium and
washed them 2 times. We used a hemacytometer and
staining with trypan blue to count the cells in each sus-
pension and assess their viability.
Cell fusion for mAbs
On the day fusion was performed, mouse lymph nodes
were harvested to obtain the lymphocytic cells. Lympho-
cytes and myeloma cells were harvested, washed, and
then mixed together. Cell fusion was performed in the
presence of polyethylene glycol (PEG). The resulting pel-
let was harvested and placed in tissue culture plates.
After incubation with hypoxanthine, aminopterin, and
thymidine (HAT) medium and feeding for 10 days, the
hybridomas were ready for screening.
Lymphocytes and Sp2/0-Ag14 myeloma cells were
mixed in a 50-ml conical tube at a ratio of 1:0.8. The
tube was then filled with serum-free RPMI medium, and
the cell mixture was subjected to centrifugation at
1350 rpm for 5 min at room temperature. After the
supernatant was aspirate and discarded, 1 ml of sterile
PEG was added to the cell pellet. The cell pellet was
then agitated for 45 sec, and 40 ml of prewarmed
serum-free RPMI medium was added to stop the reac-
tion. The mixture was then subjected to centrifugation
at 1150 rpm for 5 min at room temperature. The super-
natant was aspirated, and the cell pellet was resuspended
in HAT medium. The cells were then placed in 96-well
flat-bottom plates.
ELISA
Costar EIA/RIA plates (Fisher Scientific, Hampton, NH)
were coated with 20 ×106 cells/plate and allowed to dry
overnight before storage in a −20°C freezer until use. For
ELISA, the cells were washed with PBS containing 0.05%
Tween 20 (PBST) 3 times and blocked by incubation in
PBST containing 2% bovine serum albumin for 1 hour at
room temperature. Culture supernatant (100 μl) was
then added, and the cells were incubated for 1 hour at
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Goat anti-mouse immunoglobulin G (IgG) Fc, horserad-
ish peroxidase (HRP) conjugate (100 μl; Jackson Immu-
noresearch: 115-035-071) was then added, and the cells
were incubated at room temperature for 1 hour and
washed 5 times with PBST before the substrate was
added. Absorbance was read at 450 and 620 nm.
Western blotting
Different amounts of Rae-1β recombinant protein were
loaded onto 10% sodium dodecyl sulfate–polyacrylamide
gel and transferred to nitrocellulose membranes using
the iBlot gel transfer device (Invitrogen, Grand Island,
NY). The membranes were blotted with anit–Rae-1 pri-
mary antibody and HRP-conjugated goat anti-mouse
secondary antibody (Santa Cruz Biotechnology, Dallas,
TX) to detect the protein of interest.
Flow cytometry
Cells were gently trypsinized and washed once with
serum-containing media. The cell pellets were washed
with cold PBS free of Ca2+ and Mg2+ and then resus-
pended in 100 μl of PBS. The cells were stained with the
indicated primary and secondary antibodies for 30 min at
4°C. The expression of the indicated genes was analyzed
using a FACSCalibur flow cytometer (BD Biosciences).
DNA transfection
CT26 cells (1 × 106) were transfected with 1 μg of plas-
mid DNA using the X-tremeGENE HP DNA transfec-
tion reagent (Roche Diagnostics, Indianapolis, IN).
Immunofluorescence staining
Cells were seeded on coverslips in 12-well plates (1×105
cells/well). The next day, the cells were washed in 1×
HEPES-buffered Hank’s balanced salt solution (HEPES/
HANKS) buffer and then fixed in 1% paraformaldehyde
for 30 min. After the paraformaldehyde was removed
carefully and discarded, the cells were rinsed in PBS for
5 min 3 times. The cells were blocked in 1% goat serum
in PBS for 1 h, the primary antibody was added, and the
cells were incubated overnight at 4°C or for 2 h at room
temperature if needed. After the cells were washed with
PBS for 5 min 3 times, the secondary antibody was
added, and the cells were incubated for 60 min room
temperature. The cells were then washed with PBS for
5 min 3 times, rinsed with water, mounted on slides, and
coated with anti-fade reagent (Life Technologies,
Carlsbad, CA). The slides were stored in the dark before
they were observed under a fluorescence microscope.
Tumor inoculation and frozen tissue section preparation
Cells stably transfected with Rae-1 (CT26–Rae-1 cells)
and control cells (CT26-GFP cells) were subcutaneouslyinjected into BALB/c mice (2 × 105 cells/mouse). Four-
teen days after injection, the mice were humanely killed
and their tumors harvested. The tumors were frozen in
(optimum cutting temperature) OTC solution, and tis-
sues sections were cut and mounted on glass slides.
Immunohistochemistry staining
Frozen tumor sections were sequentially fixed with cold
acetone, acetone plus chloroform (1:1), and acetone.
Tissue sections were blocked with blocking buffer
(5% normal horse serum and 1% normal goat serum
in PBS) and then incubated with the primary anti-
body overnight at 4°C. The next day, the tissues were
incubated with the secondary antibody for 1 hour at
room temperature. Nuclei were counterstained with
hematoxylin (Sigma-Aldrich, St. Louis, MO).
Results
Establishment of CT26–Rae-1 cells
Murine colon cancer cells (CT26 cells) were stably trans-
fected with the full-length Rae-1δ gene via the retrovirus
vector pBMN-GFP. Control cells were CT26 cells trans-
fected with the pBMN-GFP vector alone. GFP-positive
colonies were selected and expanded. Rae-1 transfection
was confirmed by observation under a fluorescence
microscope. More than 90% of the cells were GFP-positive
(Figure 1A). Flow cytometry revealed that, compared with
the control cells, the Rae-1–transfected CT26 cells had a
dramatically higher level of Rae-1 expression on the cell
surface (Figure 1B). Therefore, Rae-1–positive CT26 cells
were ready for animal inoculation.
mAbs screening
Sixty different anti–Rae-1 subclones that could recognize
Rae-1–expressing cells but not the control vector–trans-
fected cells were selected for screening. For the first round
of screening for the effective antibodies, 10 groups of 6
antibodies each were subjected to a single flow cytometry
assay. We used fluorescence-activated cell sorting (FACS)
analysis of a different Rae-1–positive cell line, YAC-1, to
select the best group of hybridomas among the 10 groups
of anti–Rae-1 hybridoma culture medium mixture. Be-
cause this method quickly identifies the best group of hy-
bridomas, it was selected as the first step of the streamline
analysis (Figure 2A). A commercial anti–Rae-1 antibody
was used as the control (Figure 2B). We found that anti-
bodies from the hybridoma culture medium mixture in
group 4 could effectively stain Rae-1 on the YAC-1 cell
surface, whereas antibodies in other groups either de-
tected a low level of Rae-1 expression or failed to detect
Rae-1 expression in the same YAC-1 cells (Figure 2C).
This single step eliminated 90% of hybridoma cell lines
from further consideration.
Figure 1 Confirmation of stable transfection of Rae-1 into CT26-383 cells. A. Fluorescence microscopy image of Rae-1ε/GFP engineered
CT26-383 tumor cells. B. CT26-383 cells’ expression of Rae-1 was assessed using flow cytometry. Red dot: CT26-GFP control cells. Black solid:
CT26-383 cells.
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compare the detection sensitivity of the individual mAbs
in group 4 (Figure 2A). Compared with a commercial
anti–Rae-1 antibody, two subclones in group 4, 52A and
60A, could detect Rae-1 expression on YAC-1 cells with
high sensitivity (Figure 2D). Our results suggested that
the 52A antibody is as efficient as the commercial anti-
body and that the 60A antibody can be used for flow cy-
tometry. This step excluded the other 8 hybridomas
from further consideration.
Screening confirmed by ELISA
ELISA was used to test the ability of the purified
anti–Rae-1 52A and 60A subclone serums to recognize
Rae-1–expressing cells. The 52A and 60A serums
were diluted to different concentrations; even at very
low concentrations, the serums had strong reaction
with Rae-1–expressing cells (Figure 3A, 3B). We con-
cluded that the anti–Rae-1 mAb subclones 52A and
60A—especially 52A—had supreme binding efficiency
with Rae-1–expressing cells.
Application of the 52A anti–Rae-1 mAb
To determine the efficiency of the 52A anti–Rae-1 anti-
body, we loaded Rae-1β–Fc recombinant protein (20 μg
and 5 μg) onto 10% sodium dodecyl sulfate–polyacryl-
amide gel for immunoblotting detection. We also loaded
human IgG-Fc (20 μg) was as a negative control. Using
the 52A anti–Rae-1 antibody as a primary antibody and
a HRP-conjugated goat anti-mouse IgG secondary anti-
body, we found that Rae-1β recombinant protein, but
not the negative control, could be specifically detected
in a dose-dependent manner (Figure 4A).
Multiple cancer cell lines express Rae-1. To determine
the level of Rae-1 expression on the murine cancer cell
lines CT26, B16F10, LLC, TC1, and K7M3, we incubatedcells with the 52A anti–Rae-1 mAb and then fluorescein
isothiocyanate (FITC)-conjugated goat anti-mouse IgG
and performed flow cytometry. We found that the CT26
and B16F10 cell lines were Rae-1–negative cell lines and
the LLC, TC1, and K7M3 cell lines were Rae-1–positive
(Figure 4B).
The Rae-1 mAb could also be used for immunofluor-
escence staining. We cultured Rae-1–overexpressing
cells on coverslips in a 12-well plate, stained the cells
with the 52A anti–Rae-1 mAb and then with GFP-
conjugated anti-mouse secondary antibody or secondary
antibody alone (negative control). The coverslips were
mounted onto glass slides with 4',6-diamidino-2-pheny-
lindole (DAPI) containing anti-fade mounting buffer.
Compared with the negative controls, the cells stained
with the 52A mAb showed positive staining for Rae-1
(Figure 5). This suggests that the 52A anti–Rae-1 mAb
recognizes Rae-1–expressing cells and thus could be
used to detect Rae-1 localization in tumor cells.
We also sought to determine whether the 52A
anti–Rae-1 antibody could be used in immunohisto-
chemistry staining of frozen tissue sections, which
would facilitate identifying Rae-1’s function in vivo.
The anti–Rae-1 antibody showed positive staining on
CT26–Rae-1 tumor sections but not control CT26-GFP
tumor sections (Figure 6). Our results demonstrated
that the 52A anti–Rae-1 mAb could be applied in
immunohistochemistry staining.
Discussion
In this study, we used live cells that stably overex-
pressed the transfected mouse NKG2D ligand Rae-1as
the antigen to generate an mAb that can be used
effectively in Western blotting, flow cytometry, ELISA, and
immunofluorescence and immunohistochemistry staining
(Figures 3, 4, 5 and 6).
Figure 2 Screening of the most sensitive mAbs for Rae-1 detection. A. Flow chart of the streamlined screening process. B. Rae-1 expression
in YAC-1 cells was confirmed using a commercial phycoerythrin (PE)-anti–Rae-1 antibody. Red dot: isotype control. Black solid: PE-anti–Rae-1
antibody. C. The streamlined approach and FACS analysis were used to screen 60 subclones of hybridomas producing anti–Rae-1 mAbs. YAC-1
cells were not stained, stained with isotype control antibody, or stained with culture containing a mixture of different groups’ anti–Rae-1
mAb–producing hybridoma cells. Flow cytometry was performed to determine whether the anti–Rae-1 mixture recognizes Rae-1 expression on
YAC-1 cells. D. YAC-1 cells were not stained, stained with isotype control antibody, stained with PE-anti–Rae-1 antibody, or stained with each
anti–Rae-1 mAb–conditioned medium of group 4. Flow cytometry was performed to assess Rae-1 expression levels.
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Figure 3 The anti-Rae-1 mAb subclones 52A and 60A recognize Rae-1 expression in ELISA. The anti–Rae-1 mAb subclones 52A (A) and
60A (B) were diluted, and ELISA was performed to detect Rae-1–expressing cells.
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exclude hybridomas that produce less-sensitive mAbs
and select the hybridoma that produces a versatile mAb
for multiple applications (Figure 2A). The mAb we se-
lected, 52A anti-Rae-1, can bind Rae-1ε, which was used
to engineer the CT26 cell line, as well as Rae-1β, whose
recombinant protein was used for Western blot analysis.
Most likely, this antibody recognizes all Rae-1 subtypes
owing to the subtle difference. However, this streamlined
selection process does not consider antibodies in the
condition medium, which may lead to some mAbs that
have a high detection power being overlooked because
of their low concentrations. To avoid this concern, in-
vestigators could seed equal numbers of hybridomas,
which in theory would yield similar concentrations of
the anti–Rae-1 mAb. Of course, some hybridomas mayFigure 4 Application of the anti–Rae-1 mAb in Western blotting and
blotting using the 52A mAb. Rae-1b recombinant protein (20 μg and 5 μg
dodecyl sulfate–polyacrylamide gel. In the Western blot assay, the primary
was HRP goat anti-mouse IgG. B. Detection of Rae-1 expression levels in m
tumor cells were not stained, stained with isotype control, or stained with
flow cytometry. a, K7M3 cells; b, LLC cells; c, TC1 cells; d, CT26 cells; e, B16Fhave low rates of mAb secretion which would lower the
total concentration of mAb in the condition medium.
Most investigators likely will not need to address this
concern, however, because they would likely want to ex-
clude hybridomas that have low secretion efficiency dur-
ing the initial screening step. Another caveat of this
streamlined screening is that, because FACS is used in
the initial screening step, the best antibody for Western
blotting or immunostaining may be missed. Depending
on the primary purpose of the study in which the mAb
will be used, different applications could be used for the
initial screening step to address this concern.
Various antigens can be used to generate mAbs,
including recombinant proteins, peptides, and others
[6,7]. The system most commonly used to induce
protein expression is the prokaryotic expression system,flow cytometry. A. Detection of Rae-1 recombinant protein in Western
) and control human IgG-Fc (20 μg) were loaded onto 10% sodium
antibody was the 52A anti–Rae-1 mAb, and the secondary antibody
ultiple murine cancer cell lines using the 52A anti–Rae-1 mAb. Murine
the 52A anti–Rae-1 mAb. Rae-1 expression levels were assessed using
10 cells.
Figure 5 Application of the anti–Rae-1 mAb in cell immunofluorescence staining. Rae-1–expressing CT26 cells were stained with the 52A
anti–Rae-1 mAb and then stained with FITC-conjugated goat anti-mouse IgG secondary antibody or secondary antibody alone as a negative
control. FITC and DAPI signals were visualized using fluorescence microscopy.
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S-transferase (GST) or polyhistidine (His) is introduced
to facilitate purification. The advantages of this system
are its high efficiency and low cost. However, a bacteria-
based system is less likely to produce folded and active
proteins, especially transmembrane proteins, which tend
to have highly species-specific post-translational modifi-
cations that could be crucial for mAb generation. It is
also difficult to use bacteria-based systems to produce a
sufficient amount (~10 mg) of the soluble forms of
proteins embedded in the cell membrane and proteins
larger than 60 kD [8].
Given the limitations of bacteria-based systems, yeast,
insect [9] and mammalian expression systems [10,11]
are popular. First, eukaryotic systems have the advantageFigure 6 Application of the anti–Rae-1 mAb in immunohistochemistr
sections were stained with the 52A anti–Rae-1 mAb and then stained with
antibody alone.of conforming to the complexity of proteins that are cor-
rectly assembled and biologically functional. Second, na-
tive eukaryotic proteins tend to form insoluble inclusion
body aggregates in bacteria. Also, post-translational
modifications that are highly related to protein function,
such as glycosylation, phosphorylation, and farnesyla-
tion, are added to proteins in eukaryotic system but not
to proteins in bacteria systems [12]. However, using
eukaryotic system to induce protein expression for mAb
production is very time-consuming and costly and yields
only a small amount of purified proteins, which makes
producing at least 10 mg of purified proteins for
immunization quite challenging. Another issue with
eukaryotic systems that we have experienced is that be-
cause tags are introduced to plasmid DNA to facilitatey staining of tissue sections. CT26–Rae-1 and CT26-GFP frozen tumor
HRP-conjugated goat anti-mouse secondary antibody or secondary
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the proteins of interest are likely to be generated.
Peptides are also widely used as the epitope for mAb
generation. Phage display and a few established data-
bases are used to design peptide epitopes, but this ap-
proach invariably fails to produce antibodies that target
folded proteins.
Introducing the protein of interest into eukaryotic cells
guarantees the overexpression of correctly folded and
functional antigen protein, which is very difficult to
achieve using a bacteria-based system, especially for
glycoprotein. In immunizing animals, using a protein
that displays the natural conformation as the antigen is
more than likely to generate an effective mAb. Because
antigen proteins are expressed on the cell surface, the
protein solubility issue is avoided altogether.
The successful generation of this mAb will benefit our
current study of Rae-1 regulation. Other potential uses
of the antibody may include targeted therapy, cell ther-
apy, and imaging study applications.
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